Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT01182194
First received: August 12, 2010
Last updated: November 22, 2010
Last verified: November 2010
  Purpose

This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets (by Berlex, Inc.) following a single, oral dose (2 x 3 mg/0.02 mg tablet) in healthy, adult subjects administered under fasting conditions.


Condition Intervention Phase
Healthy
Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)
Drug: YAZ®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions.

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceuticals USA:

Primary Outcome Measures:
  • Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma) [ Time Frame: Blood samples collected over a 120 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Drospirenone Cmax.

  • AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) [ Time Frame: Blood samples collected over a 120 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Drospirenone AUC0-t.

  • AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity) [ Time Frame: Blood samples collected over a 120 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Drospirenone AUC0-inf.

  • Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma) [ Time Frame: Blood samples collected over a 72 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Ethinyl Estradiol Cmax.

  • AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) [ Time Frame: Blood samples collected over a 72 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Ethinyl Estradiol AUC0-t.

  • AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity) [ Time Frame: Blood samples collected over a 72 hour period. ] [ Designated as safety issue: No ]
    Bioequivalence based on Ethinyl Estradiol AUC0-inf.


Enrollment: 32
Study Start Date: June 2006
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Investigational Test Product
Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)
3 mg/0.02 mg Tablets
Other Name: Gianvi®
Active Comparator: Reference Listed Drug
YAZ® Tablets, 3 mg/0.02 mg
Drug: YAZ®
3 mg/0.02 mg Tablets
Other Name: Drospirenone/Ethinyl Estradiol (generic name)

Detailed Description:

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA Bioequivalence Statistical Methods

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who were informed of the nature of the study and agreed to read, review, and sign the informed consent document prior to Period I dosing.
  • Subjects who completed the screening process within 28 days prior to Period I dosing.
  • Subjects who were healthy adult menstruating women 18 to 35 years of age, inclusive, at the time of dosing.
  • Subjects with a body mass index (BMI) between 19 and 30 kg/m2, inclusive, and weigh at least 110 pounds.
  • Subjects who were healthy as documented by the medical history, physical examination, vital sign assessments, and by general observations. The physical examination also included a gynecological exam. If the subject had completed an acceptable Pap smear and gynecological exam in the previous 12 months (prior to study Day 1) and documentation of acceptable results were provided, both were deferred. Any abnormalities/deviations from the normal range which were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by the study physician and investigator prior to enrolling a volunteer in this study and for continued enrollment.
  • Female subjects who practiced an acceptable non-hormonal method of birth control as judged by the investigator(s) at least 14 days prior to Period I dosing and throughout the study and until 14 days after the Period II dosing. The acceptable non-hormonal birth control methods included: double barriers, non-hormonal releasing intrauterine device in place for at least 30 days prior to dosing, abstinence throughout the duration of the study, or surgically sterile for at least 6 months prior to Period I dosing.

Exclusion Criteria:

  • Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
  • Volunteers who report taking any oral contraceptives including estrogen and progestin combined pills and progestin only pills or patch within 28 days prior to Period I dosing, or using injectable contraceptives within 6 months of Period I dosing.
  • Volunteers who have ever had progestational hormone implants.
  • Volunteers who reported any presence of history of a clinically significant disorder involving the cardiovascular, respiratory, renal, liver, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric or epilepsy disease as determined by the clinical investigator(s).
  • Volunteers who reported any presence or history of migraines or severe headaches.
  • Volunteers who had a systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg were excluded from the study.
  • Volunteers who had a history of thrombotic disorders or have ever had cerebrovascular accident or transient ischemic attacks.
  • Volunteer with a history of breast cancer or undiagnosed breast nodules, active malignancies, or undiagnosed vaginal bleeding.
  • Volunteers having other conditions that may be aggravated by fluid retention as determined by the principal investigator.
  • Volunteers who has a history of jaundice with previous use of oral contraceptives or any other kinds of hormonal contraceptives.
  • Volunteers whose clinical laboratory test values were outside the accepted reference range and when confirmed on re-examination were deemed to be clinically significant.
  • Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
  • Volunteers who reported a history of allergic response(s) to drospirenone/ethinyl estradiol, progestin/estrogens, or related drugs.
  • Volunteers who reported the use of any systemic prescription medication in the 14 days prior to Period I dosing (with the exception of hormonal contraceptives).
  • Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
  • Volunteers who reported a history of clinically significant allergies including drug allergies.
  • Volunteers who reported a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Volunteers who reported a history of drug or alcohol addiction or abuse within the past year.
  • Volunteers who demonstrated a positive drug abuse screen for the study prior to Period I dosing.
  • Volunteers who used tobacco products in the past 6 months.
  • Volunteers who reported donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects were advised not to donate blood for 4 weeks after completing the study.
  • Volunteers who reported donating plasma within 30 days prior to Period I dosing. All subjects were advised not to donate plasma for 4 weeks after completing the study.
  • Volunteers who demonstrated a positive pregnancy screen.
  • Volunteers who are currently breastfeeding.
  • Volunteers who had used within the 3 months preceding Period I dosing and vaginally administered estrogen or progestin containing products.
  • Any volunteer who engaged in unprotected sexual intercourse during the time interval starting at 14 days prior to the first period and until 14 days after the Period II dosing.
  • Volunteers who had a hysterectomy or oophorectomy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01182194

Locations
United States, North Dakota
PRACS Institute, Ltd.
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Teva Pharmaceuticals USA
Investigators
Principal Investigator: Anthony R Godfrey, Pharm.D. PRACS Institute, Ltd.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01182194     History of Changes
Other Study ID Numbers: R06-0631
Study First Received: August 12, 2010
Results First Received: September 15, 2010
Last Updated: November 22, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Teva Pharmaceuticals USA:
Bioequivalence
Healthy Subjects

Additional relevant MeSH terms:
Estradiol
Polyestradiol phosphate
Ethinyl Estradiol
Drospirenone
Estradiol valerate
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Drospirenone and ethinyl estradiol combination
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Contraceptive Agents
Reproductive Control Agents
Therapeutic Uses
Contraceptive Agents, Female
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on September 18, 2014